Clown-Free Zone... sorry, no clowns allowed Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MythMan who wrote (227170)	3/11/2003 12:51:08 PM
From: reaper	Read Replies (3) of 436258

i'm getting long some Lilly here; this news about the Zyprexa patent is completely irrelevant and this 2% selloff is hugely overdone... 10:02AM Eli Lilly pressured by Zyprexa concerns (LLY) 54.55 -1.45: Stock under pressure this morning. Contributing to weakness is Financial Times report that a patent protecting Zyprexa, a schizophrenia treatment that is Eli Lilly's biggest selling drug, is under greater than expected risk from a court challenge by a generic competitor. The claim that Lilly withheld information from US patent officials in order to obtain the patent for Zyprexa could have more substance than thought and could be a landmark case, according to a UBS Warburg review of court documents. Cheers

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next